Lifecore Biomedical and PolyPeptide Laboratories have entered into a collaboration agreement to deliver a fully U.S.‑based end‑to‑end peptide manufacturing solution. The partnership combines PolyPeptide’s peptide synthesis and development expertise with Lifecore’s formulation, fill/finish, and packaging capabilities, enabling customers to transition from laboratory scale to commercial production within a single supply chain.
The companies highlighted that the collaboration will streamline regulatory alignment and improve reliability. Lifecore, a fully integrated contract development and manufacturing organization (CDMO) listed on NASDAQ as LFCR, brings GMP‑ready facilities and expertise in sterile injectable products. PolyPeptide, a subsidiary of PolyPeptide Group AG (SIX: PPGN), offers comprehensive peptide active pharmaceutical ingredient (API) development and manufacturing services.
Mark DaFonseca, Lifecore’s chief commercial officer, said the alliance positions the company to help customers navigate complex development challenges and bring innovative therapies to market faster. Trishul Shah, PolyPeptide’s global director of business development, added that the partnership will support laboratory transfers, equipment comparability, method transfer, and release testing, ensuring robust technical oversight across the entire process.
The companies note that the collaboration is forward‑looking and subject to risks, including the need to achieve regulatory approvals and the integration of manufacturing processes across both organizations.
Locations: Lifecore’s headquarters are in Chaska, Minnesota, and PolyPeptide’s are in Torrance, California.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.